The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma
Status:
Completed
Trial end date:
2018-12-24
Target enrollment:
Participant gender:
Summary
Multiple ascending dose study to evaluate safety/tolerability, pharmacokinetic and
pharmacodynamics effects of KA2237 (PI3 Kinase p110β/δ Inhibitor) in patients with B Cell
Lymphoma and determine the maximum tolerated dose (MTD) in Part I of the study. In Part II,
patients with B cell lymphoma will be treated with KA2237 at the MTD to evaluate safety and
efficacy in the patient population.